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Analgesic action of acetaminophen in symptomatic
osteoarthritis of the knee
H. Shen, H. Sprott, A. Aeschlimann1, R. E. Gay, B. A. Michel,
S. Gay and H. Sprott
Objectives. The study was designed to investigate the analgesic effects and mechanisms of acetaminophen (paracetamol) in
symptomatic osteoarthritis (OA) of the knee.
Methods. Twenty patients with symptomatic OA were randomly allocated to two groups treated with either acetaminophen
or rofecoxib for 3 months. Visits and measurements were scheduled upon entry (T0), at month 1 (T1) and at month 3 (T3).
The intensity of joint pain was evaluated with a 100-mm visual analogue scale (VAS). The physical function of the affected knee
was evaluated with a questionnaire comparable to the Western Ontario McMaster Universities Osteoarthritis Index
(WOMAC). Levels of serotonin, substance P (SP) and b-endorphin (BEND) were determined with commercial enzyme-linked
immunoassay kits. The expression of j opioid receptor (KOR) in peripheral mononuclear blood cells (PBMCs) was quantiﬁed
by real-time PCR.
Results. Both acetaminophen and rofecoxib relieved pain considerably but with different kinetics, and affected different
biomarkers. Rofecoxib appeared to be more efﬁcient, reducing pain intensity by 56% at T1 (P_0.01), whereas acetaminophen
reduced it by only 29%. Physical function improved in both groups by T3. Correlated with the pain relief, acetaminophen
signiﬁcantly reduced plasma BEND levels, whereas rofecoxib did not do so. In both groups plasma SP levels were elevated
compared with T0. A reduction in serum serotonin was detected in the rofecoxib group at T1 (P^0.004) but had recovered
at T3. No changes in KOR mRNA in PBMCs were observed in either group.
Conclusions. There is a correlation between reduction in circulating BEND and OA pain relief in patients treated with
acetaminophen.
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Osteoarthritis (OA) is the most common form of arthritis
and causes pain and loss of function. Its prevalence increases
with age and leads to effects on health-related quality of life
in older adults, and it is accompanied by a high economic
burden [1–4]. As our population ages and lifespan increases,
OA is expected to be the fourth leading cause of disability by
the year 2020 [1].
There is no cure for OA. Therapeutic intervention is symptom-
atic; it aims to reduce pain and improve physical function.
Based on efﬁcacy, toxicity and overall costs, acetaminophen
(paracetamol), an analgesic and antipyretic drug with weak
anti-inﬂammatory properties and few gastric and platelet side-
effects, is recommended by American College of Rheumatology
Subcommittee on Osteoarthritis [5] and the European League
Against Rheumatism [6] as the ﬁrst-line pharmacological therapy.
Although acetaminophen was introduced to medicine as early as
1893, its pharmacology remains a puzzle. It blocks prostaglandin
(PG) production in a tissue-speciﬁc manner and has been suspected
to be an inhibitor of the PGH synthase, cyclooxygenase (COX) [7].
Nevertheless, its activity cannot be fully explained by any of the
COX variants that have been identiﬁed, i.e. COX-1, COX-2
or COX-3, a recently identiﬁed COX-1 variant in dogs [8]. This
gives rise to the hypothesis that acetaminophen might function
through other mechanisms dependent on or independent of the
COX pathway.
-Endorphin (BEND) is a subtype of endogenous opioid
peptide with morphine-like analgesic effects. In addition to
antinociception, it inhibits the production of the inﬂammatory
cytokines tumour necrosis factor  and interleukin 1, the
production and enzymatic activity of matrix metalloproteinase 9
in the synovial cells of rheumatoid arthritis patients [9], and
PG production in rats [10]; therefore, it is also involved in anti-
inﬂammation and anti-arthritis processes.
Serotonin and substance P (SP) are two major inﬂammatory
mediators. Both contribute to OA pain and joint destruction
[11, 12]. SP is also involved in the production of PGE2 from
synoviocytes [13].
In the periphery,  opioid receptor (KOR) is found in ﬁbroblast-
like synoviocytes (FLS) [14] and immune cells [15]; its expression
level is inversely related to the progress of arthritis [14, 16]. In the
central nervous system, selective endogenous opioid receptor
antagonists may attenuate the central antinociceptive effect of
acetaminophen [17], implicating an interaction of acetaminophen
and opioid receptors.
In order to better understand the analgesic actions of
acetaminophen, we investigated the changes in circulating
BEND, SP, serum serotonin and KOR in OA patients treated
with acetaminophen, along with clinical indexes. Our study
revealed a correlation of joint pain relief and circulating BEND
reduction in acetaminophen-treated patients.
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Subjects and methods
Subjects
Patients and healthy subjects. Twenty patients fulﬁlled the
American College of Rheumatology criteria for knee OA [18]
accompanied by joint pain [visual analogue scale (VAS) 60mm]
were recruited to the study. They had no secondary OA as a
consequence of inﬂammation, gout, pseudogout or tumour.
Kidney insufﬁciency was also an exclusion criterion. The patients
had no OA-inﬂuencing concomitant diseases. Drug medication
with opioids was not allowed. There was a washout period from
non-steroidal anti-rheumatic agents of 14 days. After this period,
patients were randomly allocated to two groups, which were
treated with either acetaminophen up to 4 g/day (n¼ 10, age
60–77 yr, 4 males, 6 females) or rofecoxib 25mg/day (n¼ 10, age
48–80 yr, 4 males, 6 females) for 3 months. Visits and measure-
ments were scheduled upon entry (T0), at month 1 (T1) and at
month 3 (T3). The functional status of the knee joint was assessed
with a German questionnaire comparable to the Western Ontario
McMaster Universities Osteoarthritis Questionnaire (WOMAC)
[19]. The intensity of joint pain was evaluated with a 100-mm
VAS at rest. All patients completed the study except two from
the acetaminophen group after T1 (patients 3 and 6). Patient 6
withdrew from the study because of insufﬁcient pain relief.
No comorbidity was found in any patient during the study.
As a control, blood from 20 age- and gender-matched healthy
subjects was obtained from Blutspendedienst Zu¨rich. The
study was approved by the local ethical committee (Kantonale
Ethikkommission, Spezialisierte Unterkommission fu¨r
Spezialfa¨cher; reference number 343). All patients signed informed
consent. The trial is registered as ISRCTN14751911.
Methods
ELISA. The serum serotonin level was determined with
a commercial enzyme-linked immunosorbent assay (ELISA) kit
(IBL Immuno-Biological Laboratories, Hamburg, Germany)
according to the manufacturer’s instructions. For plasma BEND
and SP measurement, EDTA plasma was collected. Peptides were
extracted with a C18 SEP-Column and subsequently analysed
using BEND and SP ELISA kits (Morwell Diagnostics, Egg,
Switzerland), respectively, as described by the manufacturer.
RNA preparation and Taqman real-time RT-PCR. Peripheral
blood mononuclear cells (PBMCs) were isolated from heparin
whole blood by Ficoll gradient centrifugation using Ficoll-Paque
Plus reagent (Amersham Biosciences, Uppsala, Sweden). Total
RNA was puriﬁed with an RNeasy Mini Kit (Qiagen, Basel,
Switzerland) according to the manufacturer’s instructions.
Taqman real-time reverse transcription–PCR was performed as
described elsewhere [14]. In brief, the ﬁrst-strand cDNA was
reversed transcribed by MultiScribe Reverse Transcriptase in
the presence of random hexamer at 258C for 10min, 488C for
40min and 958C for 5min. Taqman real-time PCR was performed
in duplicate with the KOR-speciﬁc primers 50-CATCTGTTGG
CATCTCTGCAA-30, 50-TGCAAGGAGCACTCAATGACA-30
and FAM-labelled probe 50-TCTTCCCTGACTTTGGTGCCTC
CAAG-30 (anti-sense), at 958C for 15 s and 608C for 1min for
50 cycles. Relative quantities of KOR were determined with
the standard curve method, using normal human cerebellum
as calibrator and -actin as endogenous reference to normalize
RNA samples. For comparison, the relative quantity of KOR for
each patient was determined as the percentage of the average
quantity for healthy donors.
C-reactive protein. Serum C-reactive protein (CRP) was
measured with an automated laboratory method (ELISA).
Statistical analysis. Results are presented as mean±S.E.M.
The Wilcoxon signed ranks test and the Mann–Whitney test were
used to compare paired and non-paired variables, respectively.
The relationship of two variables was measured using bivariate
correlations. All analyses were performed with SPSS software 9.0
(SPSS, Chicago, IL, USA).
Results
Evaluated by VAS, both acetaminophen and rofecoxib relieved
pain considerably after 3 months of treatment (VAST3T0¼
40.7mm, P¼ 0.018; and VAST3T0¼42.5, P¼ 0.005, respec-
tively). As shown in Fig. 1, one of 10 patients in each group
(patients 8 and 110) had no pain at the end of the study. In
a comparison of the two groups, rofecoxib appeared to be
more efﬁcient, taking effect on all patients in 1 month (mean
VAST1T0¼41.5mm, P¼ 0.005), whereas in the acetaminophen
group only a moderate reduction was found at this time point
in 7/10 patients (mean VAST1T0¼21.0mm, P¼ 0.020); one
patient (patient 9) experienced more pain; two others (patients 1
and 6) showed no improvement; and patient 6 quit the study after
1 month because of dissatisfaction with pain management.
We further evaluated functional improvement using a German
questionnaire comparable to WOMAC [19]. Compared with T0,
physical function of the affected knee increased signiﬁcantly
at T1 in the rofecoxib group (P¼ 0.001) and T3 in both groups
(P50.0001 in the acetaminophen group and P¼ 0.009 in the
rofecoxib group); stiffness was alleviated only in the rofecoxib
group compared with T0 (T1, P¼ 0.005; T3, P¼ 0.033) (Table 1).
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FIG. 1. Analgesic effects of acetaminophen and rofecoxib in symptomatic OA patients, using a 100-mm VAS.
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There were no statistically signiﬁcant differences between the two
groups at any time point.
To explore the therapeutic mechanism of acetaminophen,
we measured the plasma levels of BEND and SP, as well as
serum serotonin and KOR in PBMCs in patients treated with
acetaminophen in comparison with those treated with the COX-2
inhibitor rofecoxib.
As shown in Fig. 2, BEND was reduced in 8/10 patients in
the acetaminophen group at T1, with an overall reduction of
8.62 pg/ml (T0, 30.00±10.16 pg/ml; T1, 21.38±8.52 pg/ml;
P¼ 0.017). At T3 further reductions were found in 5/8 patients.
Accordingly, the overall BEND level declined another 10.74 pg/ml,
with a total reduction of 19.36 pg/ml since T0 (P¼ 0.028).
The decrease in plasma BEND was signiﬁcantly correlated with
the corresponding VAS values (Pearson correlation¼ 0.998,
P¼ 0.037; Spearman’s  correlation coefﬁcient¼ 1.000, P50.01).
No obvious changes were found in the rofecoxib group (Fig. 2)
(T0, 18.56±2.09 pg/ml; T1, 20.20±3.10 pg/ml; T3, 18.47±
2.30 pg/ml). There was no statistically signiﬁcant difference
between the two groups at T0 (P¼ 0.965). Thus, in pain manage-
ment acetaminophen may play a role through the BEND pathway,
whereas rofecoxib does not [20].
At T1, serum serotonin was decreased in 7/10 patients in the
rofecoxib group (Fig. 3), showing an average reduction of 13.25%
from T0 (132.15±14.86 ng/ml) to T1 (114.64±13.61 ng/ml,
P¼ 0.037), but had returned at T3 in ﬁve of the seven patients to
an overall level comparable to that at T0 (146.49±26.92 ng/ml;
T3 vs T1, P¼ 0.059; T3 vs T0, P¼ 0.575). With regard to the
acetaminophen group, no signiﬁcant changes were detected during
the study (T0, 124.40±17.01 ng/ml; T1, 124.12±17.04 ng/ml;
T3¼ 136.25±16.40 ng/ml).
We compared the plasma SP level in the two groups. As shown
in the upper panel in Fig. 4, at T1 increases in plasma SP were
TABLE 1. Changes in WOMAC index in OA patients treated with
acetaminophen or rofecoxib in comparison with baseline
Acetaminophen Rofecoxib
Pain
Baseline (T0) 2.74 3.62
Change at T1 0.26 1.6
Change at T3 0.74 1.12
Stiffness
Baseline (T0) 2.85 4.2
Change at T1 0.15 1.3
Change at T3 0.54 0.8
Activity
Baseline (T0) 2.43 3.69
Change at T1 0.05 1.19
Change at T3 1.06 0.98
T1, 1 month after baseline; T3, 3 months after baseline.
0
10
20
30
40
50
60
70
80
90
100
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 110
T0 T1 T3
Acetaminophen Rofecoxib
FIG. 2. Changes in plasma -endorphin (BEND) in OA patients treated with acetaminophen or rofecoxib.
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FIG. 3. Serum serotonin in OA patients treated with acetaminophen or rofecoxib.
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found in 6/10 acetaminophen- and 7/10 rofecoxib-treated
patients and these resulted in overall increases of 75.68 and
40.66% in the two groups (acetaminophen, T0, 3.70±0.42 pg/ml,
T1, 6.50±1.79 pg/ml, P¼ 0.041; rofecoxib, T0, 4.55±0.25 pg/ml,
T1, 6.40±0.95 pg/ml, P¼ 0.046). From T1 to T3, reductions in SP
were found in three of the six patients treated with acetaminophen,
but in two of them SP remained higher than at baseline, whereas
moderate increases were detected in two other patients in the
group. With regard to the rofecoxib group, SP was decreased in
six of the total of 10 patients, but remained higher or equal to
SP at T0 in 8/10 patients. Therefore, despite moderate overall
reductions compared with T1, at T3 there were still 35.14 and
34.07% increases in SP in the acetaminophen and rofecoxib
groups, respectively, compared with T0 (acetaminophen, T3,
5.00±0.71 pg/ml; rofecoxib, T3, 6.10±1.03 pg/ml). No statistical
differences were found between T1 and T3 in either group or, at
any time point, between the two groups. Because the concentra-
tions of peripheral SP could be affected by various inﬂammatory
diseases [21, 22], we further evaluated the CRP level in these
patients; CRP generally reﬂects the presence and intensity of an
inﬂammatory process. In contrast to SP, the average levels of CRP
at T0, T1 and T3 were normal in both groups (acetaminophen, T0,
5.61±3.50mg/ml, T1, 1.64±0.39mg/ml, T3, 2.24±0.72mg/ml;
rofecoxib, T0, 6.43±2.98mg/ml, T1, 3.19±1.20mg/ml, T3,
2.81±0.66mg/ml). Abnormal elevation of CRP was detected in
only one patient in each group at the start of the study (patients 4
and 16); levels returned to normal after 1 month’s medication,
coinciding with pain relief but not with the increase in SP (Fig. 4,
lower panel).
KOR mRNA was detected in PBMCs of 85% OA patients
enrolled in the study (8/10 in the acetaminophen group, 9/10 in
the rofecoxib group) but at signiﬁcantly low levels (P50.001): only
16.46±2.77% (acetaminophen) and 13.48±2.40% (rofecoxib)
of the average for healthy individuals (n¼ 20) at T0. No obvious
modulation effect was found after either acetaminophen or
rofecoxib medication at T1 (acetaminophen, 14.18±4.44%;
rofecoxib, 15.82±3.91%) and T3 (acetaminophen, 15.83±
4.29%; rofecoxib, 13.44±3.04%), and no difference was observed
between the two groups at any time point investigated.
Discussion
To explore the therapeutic mechanism of acetaminophen in
symptomatic OA management, we compared its effects on joint
pain and function with those of the COX-2 inhibitor rofecoxib.
Although both drugs relieved pain and improved the physical
function of OA patients signiﬁcantly in 3 months, they
exhibited different kinetics, indicating different pharmacological
mechanisms.
In the blood, BEND is released not only from pituitary gland
[23] but also from immune cells [24]. BEND can bind to its
receptors locally through the circulation. Endings of primary
sensory neurons, synovial tissues [25], osteoarthritic cartilage and
chondrocytes [26] contain BEND binding sites. Activation of
BEND receptors in the joints can inhibit local pain directly [27, 28].
At the start of the study, the average level of BEND in the
acetaminophen-treated group was slightly higher than that in the
rofecoxib group as well as in age- and gender-matched healthy
subjects (19.5±1.48 pg/ml, n¼ 20); however, there was no statis-
tically signiﬁcant difference (acetaminophen vs rofecoxib,
P¼ 0.965; acetaminophen vs healthy subjects, P¼ 0.764). Also,
the BEND level in patients was not related to the severity of pain in
either group. Surprisingly, after acetaminophen administration,
plasma BEND was reduced in correlation with the pain relief.
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FIG. 4. Changes in plasma SP (upper panel) and CRP (lower panel) in OA patients treated with acetaminophen or rofecoxib.
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This effect was acetaminophen-speciﬁc and independent of the
rofecoxib-affected COX-2 pathway, as no changes were found
at any time point in the rofecoxib-treated group. Accumulation
and binding of BEND with its receptors in local tissue may lead
not only to pain relief but also to a reduction in free BEND
in the circulation. There is increasing evidence that immune-
derived BEND is critical for peripheral analgesia [29]. In a
painful inﬂammation model, circulating leucocytes underwent
site-directed migration and released BEND locally [30].
Acetaminophen may play a direct or indirect role in promoting
local accumulation of BEND. In line with this, Stein’s group
reported increased transport of immune-derived BEND after local
injury [31]. Further investigation is to be undertaken to test the
hypothesis.
In both OA groups, the expression level of KOR mRNA in
PBMCs is dramatically lower that that in healthy subjects. This is
in line with our observations in FLS [14]. Nevertheless, neither
acetaminophen nor rofecoxib had any modulating effects on
KOR mRNA in these patients. Thus, unlike in the central nervous
system [17], circulating KOR may not be related to the analgesic
action of acetaminophen. However, this does not exclude the
possibility that acetaminophen may function through other
subtypes of peripheral opioid receptors.
Rofecoxib (Vioxx) is one of the selective COX-2 inhibitors,
which were originally developed to reduce the gastrointestinal side-
effects of other non-steroidal anti-inﬂammatory drugs (NSAIDs),
possibly due to the inhibition of COX-1. It was voluntarily
withdrawn from the market at the end of September 2004 because
of the risk of heart attack and stroke after long-term medication
(longer than 18 months). We included rofecoxib in our study as a
COX-2 inhibitor control. This study was performed and accom-
plished before the withdrawal of rofecoxib. No severe adverse
effects were found during the course of the study. We observed a
temporary reduction in serotonin in the rofecoxib group, indi-
cating that rofecoxib might act on the serotonin pathway and
secondarily control the release of inﬂammatory mediators besides
its known anti-inﬂammatory action as a selective COX-2 inhibitor.
Despite effective pain management and functional improve-
ment, plasma SP was increased signiﬁcantly in the patients treated
with either acetaminophen or rofecoxib. Peripheral SP is released
from nerve endings, inﬂammatory cells and also FLS [21, 22]. Its
concentration in plasma could be affected by various inﬂammatory
diseases [21]. Using CRP as a marker of inﬂammation, we did not
observe any correlation between SP and CRP levels, suggesting
that the increase in SP is less likely to be a result of inﬂammatory
conditions in the patients we investigated. BEND is known to
be able to suppress SP release [32]. The reduction in peripheral
BEND could facilitate SP release. Nevertheless, such a correlation
was only found in two acetaminophen-treated patients. In fact,
the increase in SP was found not only in acetaminophen-treated
patients with lower plasma BEND but also in rofecoxib-treated
patients with a normal level of BEND. Thus, the increase in SP
may not result from a decrease in BEND. Acetaminophen and
rofecoxib may share some general machinery in the induction of
SP; this needs to be investigated further with a control group
without NSAIDs.
Conclusions
We investigated the actions of acetaminophen in the symptomatic
management of OA. This investigation lacked an NSAID-free
control group, which is a weakness of the study. However,
comparison with such a group could cause ethical problems
because pain medication (at least a rescue medication) for
symptomatic OA with a pain intensity of VAS 60mm has to be
provided. NSAIDs and opioids were not allowed in our study
design. Acetaminophen (the rescue medication in most clinical
trials) is disadvantageous because of the study aim. Our data
showed that acetaminophen medication improved joint function
and relieved pain and that this was accompanied by a decrease
in BEND in the circulation. This suggests that acetaminophen,
in addition to being a COX inhibitor, might function through
the BEND pathway via a novel mechanism, to be further
characterized.
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